X4 PHARMACEUTICALS INC's ticker is XFOR and the CUSIP is 98420X103. A total of 55 filers reported holding X4 PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 1.29 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $708,500 | -43.8% | 650,000 | 0.0% | 0.00% | -50.0% |
Q2 2023 | $1,261,000 | +123.0% | 650,000 | 0.0% | 0.00% | +100.0% |
Q1 2023 | $565,500 | -12.4% | 650,000 | 0.0% | 0.00% | 0.0% |
Q4 2022 | $645,450 | -85.2% | 650,000 | -74.5% | 0.00% | -88.2% |
Q3 2022 | $4,354,000 | +176.3% | 2,546,446 | +55.9% | 0.02% | +142.9% |
Q2 2022 | $1,576,000 | -44.9% | 1,633,204 | 0.0% | 0.01% | -36.4% |
Q1 2022 | $2,858,000 | -23.6% | 1,633,204 | 0.0% | 0.01% | -26.7% |
Q4 2021 | $3,740,000 | – | 1,633,204 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Polaris Venture Management Co. V, L.L.C. | 311,492 | $2,109,000 | 3.48% |
SV Health Investors, LLC | 311,490 | $2,109,000 | 1.07% |
Bain Capital Life Sciences Investors, LLC | 1,648,485 | $11,160,000 | 1.04% |
New Leaf Venture Partners, L.L.C. | 335,000 | $2,268,000 | 0.91% |
Ikarian Capital, LLC | 724,680 | $4,907,000 | 0.36% |
BVF INC/IL | 792,892 | $5,368,000 | 0.29% |
Opaleye Management Inc. | 75,000 | $508,000 | 0.10% |
Orbimed Advisors | 1,086,493 | $7,356,000 | 0.09% |
RA Capital Management | 559,494 | $3,788,000 | 0.07% |
Bleichroeder LP | 35,730 | $242,000 | 0.04% |